32 results on '"Passamonti, F."'
Search Results
2. P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
- Author
-
Kiladjian, J.-J., primary, Tefferi, A., additional, Passamonti, F., additional, Vannucchi, A., additional, Talpaz, M., additional, Cervantes, F., additional, Harrison, C. N., additional, Mesa, R. A., additional, Mascarenhas, J., additional, Schaap, N., additional, Verstovsek, S., additional, Devos, T., additional, Rose, S., additional, Zhang, J., additional, Sy, O., additional, and Pardanani, A., additional
- Published
- 2022
- Full Text
- View/download PDF
3. IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA
- Author
-
Condoluci, A., primary, Terzi‐di‐Bergamo, L., additional, Forestieri, G., additional, Moia, R., additional, Deambrogi, C., additional, Deodato, M., additional, Frustaci, A. M., additional, Merli, M., additional, Mattarucchi, R., additional, Autore, F., additional, Fahrni, G., additional, Scarfò, L., additional, Gussetti, D., additional, Bulian, P., additional, Zanatta, A., additional, Spina, V., additional, Faderl, M. R., additional, Bruscaggin, A., additional, Pini, K., additional, Piffaretti, D., additional, Koch, R., additional, Pirosa, M. C., additional, Cittone, M. G., additional, Passweg, J., additional, Cavalli, F., additional, Zucca, E., additional, Gerber, B., additional, Gillessen, S., additional, Stüssi, G., additional, Gattei, V., additional, Ghia, P., additional, Gregor, M., additional, Laurenti, L., additional, Passamonti, F., additional, Tedeschi, A., additional, Gaidano, G., additional, and Rossi, D., additional
- Published
- 2021
- Full Text
- View/download PDF
4. ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAY
- Author
-
Terzi di Bergamo, L, primary, Forestieri, G, additional, Loh, J. W, additional, Singh, A, additional, Spina, V, additional, Zucchetto, A, additional, Condoluci, A, additional, Faderl, M, additional, Koch, R, additional, Bruscaggin, A, additional, Pini, K, additional, Wu, W, additional, Piffaretti, D, additional, Bittolo, T, additional, Tissino, E, additional, Paoli, L, additional, Deambrogi, C, additional, Frustaci, A. M, additional, Autore, F, additional, Merli, M, additional, Scarfò, L, additional, Rasi, S, additional, Passweg, J, additional, Moia, R, additional, Martines, C, additional, Ghia, P, additional, Cavalli, F, additional, Zucca, E, additional, Gerber, B, additional, Gillessen, S, additional, Stüssi, G, additional, Montillo, M, additional, Passamonti, F, additional, Gregor, M, additional, Laurenti, L, additional, Tedeschi, A, additional, Gaidano, G, additional, Efremov, D, additional, Gattei, V, additional, Khiabanian, H, additional, and Rossi, D, additional
- Published
- 2021
- Full Text
- View/download PDF
5. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA
- Author
-
Bonfiglio, F., primary, Bruscaggin, A., additional, Guidetti, F., additional, Terzi di Bergamo, L., additional, Faderl, M., additional, Spina, V., additional, Condoluci, A., additional, Bonomini, L., additional, Forestieri, G., additional, Koch, R., additional, Piffaretti, D., additional, Pini, K., additional, Pirosa, M. C., additional, Cittone, M. G., additional, Arribas, A., additional, Lucioni, M., additional, Ghilardi, G., additional, Wu, W., additional, Arcaini, L., additional, Baptista, M. J., additional, Bastidas, G., additional, Bea, S., additional, Boldorini, R., additional, Broccoli, A., additional, Canzonieri, V., additional, Cascione, L., additional, Ceriani, L., additional, Cogliatti, S., additional, Derenzini, E., additional, Devizzi, L., additional, Dietrich, S., additional, Elia, A. R., additional, Facchetti, F., additional, Gaidano, G., additional, Garcia, J. F., additional, Gerber, B., additional, Ghia, P., additional, Silva, M. G., additional, Gritti, G., additional, Guidetti, A., additional, Hitz, F., additional, Inghirami, G., additional, Ladetto, M., additional, Lopez‐Guillermo, A., additional, Lucchini, E., additional, Maiorana, A., additional, Marasca, R., additional, Matutes, E., additional, Meignin, V., additional, Merli, M., additional, Moccia, A., additional, Mollejo, M., additional, Montalban, C., additional, Novak, U., additional, Oscier, D. G., additional, Passamonti, F., additional, Piazza, F., additional, Pizzolitto, S., additional, Sabattini, E., additional, Salles, G., additional, Santambrogio, E., additional, Scarfó, L., additional, Stathis, A., additional, Stüssi, G., additional, Geyer, J. T., additional, Tapia, G., additional, Thieblemont, C., additional, Tousseyn, T., additional, Tucci, A., additional, Visco, C., additional, Vitolo, U., additional, Zenz, T., additional, Zinzani, P. L., additional, Khiabanian, H., additional, Calcinotto, A., additional, Bertoni, F., additional, Bhagat, G., additional, Campo, E., additional, Leval, L., additional, Dirnhofer, S., additional, Pileri, S. A., additional, Piris, M. Án., additional, Traverse‐Glehen, A., additional, Tzankov, A., additional, Paulli, M., additional, Ponzoni, M., additional, Mazzucchelli, L., additional, Cavalli, F., additional, Zucca, E., additional, and Rossi, D., additional
- Published
- 2021
- Full Text
- View/download PDF
6. Septic pyomyositis, multiple pelvic osteomyelitis and thrombosis in a Thoroughbred foal
- Author
-
Pressanto, M. C., primary, Beccati, F., additional, Stefanetti, V., additional, Passamonti, F., additional, Pilati, N., additional, and Pepe, M., additional
- Published
- 2018
- Full Text
- View/download PDF
7. DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
- Author
-
Zinzani, P., primary, Wagner-Johnston, N., additional, Miller, C., additional, Ardeshna, K., additional, Tertreault, S., additional, Assouline, S., additional, Mayer, J., additional, Passamonti, F., additional, Lunin, S., additional, Pettitt, A., additional, Nagy, Z., additional, Tournilhac, O., additional, Abou-Nassar, K., additional, Crump, M., additional, Jacobsen, E., additional, De Vos, S., additional, Youssoufian, H., additional, Porter, J., additional, Prado, S., additional, and Flinn, I., additional
- Published
- 2017
- Full Text
- View/download PDF
8. Umbilical infections in foals: microbiological investigation and management
- Author
-
Rampacci, E., primary, Passamonti, F., additional, Bottinelli, M., additional, Stefanetti, V., additional, Cercone, M., additional, Nannarone, S., additional, Gialletti, R., additional, Beccati, F., additional, Coletti, M., additional, and Pepe, M., additional
- Published
- 2017
- Full Text
- View/download PDF
9. DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS
- Author
-
Merli, M., primary, Alric, L., additional, Mannelli, L., additional, De Angelis, F., additional, Ferrari, A., additional, Capecchi, M., additional, Pirisi, M., additional, Visco, C., additional, Piazza, F., additional, Loustaud-Ratti, V., additional, Goldaniga, M., additional, Zancanella, M., additional, Cencini, E., additional, Marino, D., additional, Benanti, F., additional, Rumi, M., additional, Frigeni, M., additional, Gotti, M., additional, Sciarra, R., additional, Ferretti, V., additional, Grossi, P., additional, Passamonti, F., additional, Bruno, R., additional, and Arcaini, L., additional
- Published
- 2017
- Full Text
- View/download PDF
10. Stored Canine Whole Blood Units: What is the Real Risk of Bacterial Contamination?
- Author
-
Miglio, A., primary, Stefanetti, V., additional, Antognoni, M.T., additional, Cappelli, K., additional, Capomaccio, S., additional, Coletti, M., additional, and Passamonti, F., additional
- Published
- 2016
- Full Text
- View/download PDF
11. Septic tendonitis of the deep digital flexor tendon in a Thoroughbred horse referred for weight loss and intermittent fever
- Author
-
Santinelli, I., primary, Beccati, F., additional, Passamonti, F., additional, and Pepe, M., additional
- Published
- 2015
- Full Text
- View/download PDF
12. Causes of equine abortion, stillbirth and neonatal death in central Italy
- Author
-
Marenzoni, M. L., primary, Lepri, E., additional, Proietti, P. Casagrande, additional, Bietta, A., additional, Coletti, M., additional, Timoney, P. J., additional, and Passamonti, F., additional
- Published
- 2012
- Full Text
- View/download PDF
13. Epidemiological Survey on Equine Cryptosporidium and Giardia Infections in Italy and Molecular Characterization of Isolates
- Author
-
Veronesi, F., primary, Passamonti, F., additional, Cacciò, S., additional, Diaferia, M., additional, and Piergili Fioretti, D., additional
- Published
- 2009
- Full Text
- View/download PDF
14. Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis
- Author
-
Rumi, E., primary, Passamonti, F., additional, Pagano, L., additional, Ammirabile, M., additional, Arcaini, L., additional, Elena, C., additional, Flagiello, A., additional, Tedesco, R., additional, Vercellati, C., additional, Marcello, A. P., additional, Pietra, D., additional, Moratti, R., additional, Cazzola, M., additional, and Lazzarino, M., additional
- Published
- 2009
- Full Text
- View/download PDF
15. Clinical, serological and molecular investigations of ehv-1 and ehv-4 in 15 unweaned thoroughbred foals
- Author
-
Marenzoni, M. L., primary, Passamonti, F., additional, Cappelli, K., additional, Veronesi, F., additional, Capomaccio, S., additional, Verini Supplizi, A., additional, Valente, C., additional, Autorino, G., additional, and Coletti, M., additional
- Published
- 2008
- Full Text
- View/download PDF
16. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients
- Author
-
Brazzelli, V, primary, Prestinari, F, additional, Barbagallo, T, additional, Rona, C, additional, Orlandi, E, additional, Passamonti, F, additional, Locatelli, F, additional, Zecca, M, additional, Villani, S, additional, and Borroni, G, additional
- Published
- 2007
- Full Text
- View/download PDF
17. Klebsiella pneumoniae infection in Italian rabbits
- Author
-
Coletti, M., primary, Passamonti, F., additional, Del Rossi, E., additional, Franciosini, M. P., additional, and Setta, B., additional
- Published
- 2001
- Full Text
- View/download PDF
18. Immunogenicity and clinical efficacy of anti‐SARS‐CoV‐2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients
- Author
-
Marco Salvini, Camilla Damonte, Lorenzo Mortara, Fabrizio Maggi, Antonino Bruno, Giacomo Pellegrini, Barbara Mora, Marco Brociner, Alessia Ingrassia, Roberta Mattarucchi, Benedetta Bianchi, Davide Sirocchi, Stefania Agnoli, Elisa Rumi, Michele Merli, Alessandro Fossati, Susanna Bassi, Raffaella Bombelli, Matteo Gallazzi, Oscar Borsani, Andreina Baj, Matteo Franchi, Paolo A. Grossi, Francesco Passamonti, Salvini, M, Damonte, C, Mortara, L, Maggi, F, Bruno, A, Pellegrini, G, Mora, B, Brociner, M, Ingrassia, A, Mattarucchi, R, Bianchi, B, Sirocchi, D, Agnoli, S, Rumi, E, Merli, M, Fossati, A, Bassi, S, Bombelli, R, Gallazzi, M, Borsani, O, Baj, A, Franchi, M, Grossi, P, and Passamonti, F
- Subjects
Treatment Outcome ,Hematologic Neoplasms ,Vaccination ,Humans ,COVID-19 ,Viral ,Prospective Studies ,Hematology ,Antibodies, Viral ,Immunogenicity, SARS-CoV-2, COVID-19 vaccination, hematological malignancies ,Antibodies - Published
- 2022
19. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease
- Author
-
Emanuela Bonoldi, Francesco Passamonti, Sara Burcheri, Mario Lazzarino, Michele Spina, Teresio Motta, L. Uziel, Vincenzo Canzonieri, Monica Crugnola, Marco Paulli, Intergruppo Italiano Linfomi, Francesca Montanari, Enrica Morra, Andrea Rossi, Andrea Gallamini, M Montanari, Marco Lucioni, Antonio Ramponi, Luca Arcaini, Cristiana Pascutto, Arcaini, L, Paulli, M, Burcheri, S, Rossi, A, Spina, M, Passamonti, F, Lucioni, M, Motta, T, Canzonieri, V, Montanari, M, Bonoldi, E, Gallamini, A, Uziel, L, Crugnola, M, Ramponi, A, Montanari, F, Pascutto, C, Morra, E, and Lazzarino, M
- Subjects
Male ,hepatitis C virus ,medicine.medical_specialty ,Pathology ,Lymphoma, B-Cell ,Follicular lymphoma ,Hepacivirus ,Gastroenterology ,Disease-Free Survival ,Immunophenotyping ,Rare Diseases ,International Prognostic Index ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Nodal marginal zone B cell lymphoma ,Cyclophosphamide ,Survival analysis ,Aged ,Univariate analysis ,Hematology ,business.industry ,nodal marginal zone lymphoma ,low-grade non-Hodgkin lymphoma ,marginal zone ,prognosis ,Middle Aged ,medicine.disease ,Marginal zone ,Hepatitis C ,Survival Analysis ,Lymphoma ,Doxorubicin ,Vincristine ,Multivariate Analysis ,Prednisone ,Female ,business - Abstract
This study defined the clinical features and assessed the prognosis of 47 patients (17 males, 30 females, median age 63 years) with primary nodal marginal zone B-cell lymphoma. Forty-five per cent had stage IV disease. Hepatitis C virus serology was positive in 24%. According to the Follicular Lymphoma International Prognostic Index (FLIPI), 33% were classified as low-risk, 34% as intermediate-risk, and 33% as high-risk. The 5-year overall survival (OS) was 69%. In univariate analysis worse OS was associated with: FLIPI (P = 0.02), age > 60 years (P = 0.05) and raised lactate dehydrogenase (P = 0.05). In multivariate analysis, only FLIPI predicted a worse OS (P = 0.02).
- Published
- 2007
20. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis - prognostic relevance is independent of IPSS or karyotype
- Author
-
Curtis A. Hanson, Animesh Pardanani, Kebede Hussein, Ayalew Tefferi, Sergio Siragusa, Francisco Cervantes, Francesco Passamonti, Susan M. Schwager, Tefferi, A, Siragusa, S, Hussein, K, Schwager, SM, Hanson, CA, Pardanani, A, Cervantes, F, and Passamonti, F
- Subjects
Adult ,Male ,medicine.medical_specialty ,transfusion, myelofibrosis ,PROGNOSIS ,medicine.medical_treatment ,myelofibrosis ,Hematopoietic stem cell transplantation ,Severity of Illness Index ,Settore MED/15 - Malattie Del Sangue ,Risk Factors ,Internal medicine ,Severity of illness ,medicine ,Humans ,Myelofibrosis ,Survival analysis ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chromosome Aberrations ,Hematology ,business.industry ,Patient Selection ,Myelodysplastic syndromes ,Hematopoietic Stem Cell Transplantation ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Survival Analysis ,Surgery ,Primary Myelofibrosis ,International Prognostic Scoring System ,RBC transfusiion ,Female ,Erythrocyte Transfusion ,business ,Follow-Up Studies - Abstract
The International Prognostic Scoring System (IPSS) and karyotype are useful tools for risk stratification in primary myelofibrosis (PMF). We examined the additional prognostic impact of red blood cell transfusion need among 254 consecutive patients (median age, 59 years). Sixty-two patients ( approximately 24%) required transfusions at diagnosis whereas 22 ( approximately 9%) became transfusion-dependent and 170 remained transfusion-independent during the first year postdiagnosis; after a median follow-up of 55 months, the respective median survivals were 35, 25, and 117 months (P < 0.01). Multivariable analysis confirmed the IPSS- and karyotype-independent prognostic weight of transfusion status. Among IPSS intermediate-1 risk patients, overall median survival of 82 months was modified to 60 or 118 months, based on presence or absence of transfusion need, respectively (P < 0.01). The corresponding figures for intermediate-2/high risk patients were 30 and 64 months (P < 0.01). Documented causes of death did not include iron overload. We conclude that transfusion status in PMF downgrades or upgrades prognosis within specific IPSS categories; transfusion need is a marker of aggressive disease biology in PMF, as it is in myelodysplastic syndromes. (c) 2009 Wiley-Liss, Inc
- Published
- 2009
21. Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives.
- Author
-
Harrison CN, Kiladjian JJ, Koschmieder S, and Passamonti F
- Subjects
- Humans, Janus Kinase Inhibitors therapeutic use, Hematopoietic Stem Cell Transplantation, Primary Myelofibrosis therapy
- Abstract
The current standard-of-care for treatment of myelofibrosis (MF) comprises inhibitors of the Janus kinase (JAK)/signal transducers and activators (STAT) pathway; however, despite their ability to alleviate symptoms, they do not appear to modify underlying disease and have not demonstrated substantial survival benefit. Allogeneic-hematopoietic stem cell transplantation remains the only curative option for patients with MF but is limited to a subset of high-risk and fit patients. Early disease modification could positively affect disease trajectory for lower risk patients with MF as well as those with conditions that can precede MF, such as polycythemia vera and essential thrombocythemia. Here, the authors discuss critical unmet needs in the MF treatment paradigm, including: the need for safe, impactful therapies for lower risk patients, thus allowing intervention when success is most likely; better development of first-line therapies (likely highly novel or combination strategies) for intermediate-risk/higher risk patients; and approved drugs to manage cytopenia. Finally, a consensus definition of disease modification is needed that informs trial design, allowing the development of clinical end points that enable understanding of therapies and responses and that facilitate the development of therapies that work according to this definition. Through close collaboration between clinicians, patients, and the pharmaceutical industry, better efforts to define benefit and identify patients most likely to benefit from a particular combination or treatment strategy should enable the development of more effective and safe treatments to extend and improve quality of life for patients with MF., (© 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF
22. Long-term outcomes of the Italian Mycobacterium avium subspecies paratuberculosis control programme for dairy cattle.
- Author
-
Musolino N, Rampacci E, Tolasi C, Beccati F, and Passamonti F
- Subjects
- Cattle, Animals, Retrospective Studies, Italy epidemiology, Dairying, Paratuberculosis epidemiology, Paratuberculosis prevention & control, Paratuberculosis microbiology, Mycobacterium avium subsp. paratuberculosis, Cattle Diseases epidemiology, Cattle Diseases prevention & control, Cattle Diseases microbiology
- Abstract
Background: The considerable epidemiological and economic implications of paratuberculosis, caused by Mycobacterium avium subspecies paratuberculosis (MAP), have placed importance on control efforts aimed at preventing MAP transmission. In this context, Italy issued national guidelines for the control and status certification of MAP in dairy cattle in 2013., Methods: We assessed the long-term outcomes of the Italian MAP control programme for 14 dairy farms located in northern Italy by retrospectively reviewing the results of yearly serological tests, presence of clinical cases, MAP faecal shedding in serologically positive animals, farm management and health ranking as indicators of herd health between 2014 and 2021., Results: A significantly higher number of serologically positive animals were observed between 2014 and 2016 than between 2017 and 2021, as well as an improving trend in the paratuberculosis health ranking for nine of the 14 farms. No clinical cases were reported. MAP shedding was detected in 9.4% of serologically positive animals. Discarding colostrum and prioritised culling of seropositive animals assisted by adoption of standardised serological testing were presumed to have a key role in MAP control, despite the reluctance of some farmers to address hygienic issues and improve the separation of calves from adult animals., Limitations: The small number of farms included in this study and the fact that these were not randomly selected may limit the generalisability of the findings., Conclusions: The Italian paratuberculosis control plan has provided measures to limit the uncontrolled spread of MAP infection within and between herds by promoting animal trading between farms certified as negative or low risk., (© 2024 British Veterinary Association.)
- Published
- 2024
- Full Text
- View/download PDF
23. New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-X L /BCL-2 inhibition with navitoclax.
- Author
-
Pemmaraju N, Garcia JS, Perkins A, Harb JG, Souers AJ, Werner ME, Brown CM, and Passamonti F
- Subjects
- Humans, Janus Kinase 2, Proto-Oncogene Proteins c-bcl-2, Nitriles therapeutic use, Primary Myelofibrosis drug therapy, Janus Kinase Inhibitors pharmacology, Janus Kinase Inhibitors therapeutic use, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use
- Abstract
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-X
L ) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment., (© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)- Published
- 2023
- Full Text
- View/download PDF
24. Diagnostic characteristics of refractometry cut-off points for the estimation of immunoglobulin G concentration in mare colostrum.
- Author
-
Rampacci E, Mazzola K, Beccati F, and Passamonti F
- Subjects
- Pregnancy, Horses, Animals, Female, Immunoglobulin G, Immunodiffusion veterinary, Immunodiffusion methods, Sensitivity and Specificity, Animals, Newborn, Colostrum, Refractometry veterinary
- Abstract
Background: Feeding foals with poor quality colostrum predisposes them to failure of passive transfer (FPT). FPT is a major risk factor for neonatal infections., Objectives: To assess the optimal cut-offs for the optical (OR) and digital (DR) refractometer and determine their accuracy for poor quality colostrum diagnosis., Study Design: A diagnostic validation study., Methods: Eighty-one colostrum samples and sera were collected from broodmares and their neonatal foals, respectively. Colostral and serum IgG concentrations were measured by radial immunodiffusion (RID), DR and OR. Correlation coefficients were calculated. ROC curves were generated to identify optimal cut-offs for the refractometers and their diagnostic characteristics were evaluated., Results: The optimal cut-offs for DR and OR were ≤23.75% and 23.9%, respectively. The sensitivity and specificity of the DR were 93.3% (95% CI: 66.0-99.7) and 87.9% (95% CI: 77.0-94.3) to detect colostral IgG <60 g/L, respectively. The sensitivity and specificity of the OR were 93.3% (95% CI: 66.0-99.7) and 81.8% (95% CI: 70.0-89.9), respectively. DR and OR had negative predictive values of 98.3% (95% CI: 89.7-99.9) and 98.2% (95% CI: 89.0-99.9), respectively, whilst positive predictive values were lower. No maternal variable, including breed, significantly influenced colostral IgG concentrations. Fifteen out of 81 colostrum samples had IgG <60 g/L. FPT and PFPT were diagnosed in 4/81 and 10/81 foals, respectively. Nine out of 14 animals with FPT/PFPT suckled colostrum with IgG <60 g/L. A moderate correlation (r
s 0.542; P = .01) was observed between IgG concentrations measured by RID in sera and colostrum., Main Limitations: A smaller number of samples than the size requirement based on a priori estimate of specificity and the low prevalence of poor quality colostrum., Conclusions: The method has the potential to reliably differentiate between good and poor quality colostrum. Assessing colostrum quality by refractometry may be an indicator of passive transfer of immunity., (© 2022 The Authors. Equine Veterinary Journal published by John Wiley & Sons Ltd on behalf of EVJ Ltd.)- Published
- 2023
- Full Text
- View/download PDF
25. Defining disease modification in myelofibrosis in the era of targeted therapy.
- Author
-
Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, Oh ST, Passamonti F, Döhner K, and Mead AJ
- Subjects
- Disease Progression, Hematopoiesis, Humans, Primary Myelofibrosis drug therapy
- Abstract
The development of targeted therapies for the treatment of myelofibrosis highlights a unique issue in a field that has historically relied on symptom relief, rather than survival benefit or modification of disease course, as key response criteria. There is, therefore, a need to understand what constitutes disease modification of myelofibrosis to advance appropriate drug development and therapeutic pathways. Here, the authors discuss recent clinical trial data of agents in development and dissect the potential for novel end points to act as disease modifying parameters. Using the rationale garnered from latest clinical and scientific evidence, the authors propose a definition of disease modification in myelofibrosis. With improved overall survival a critical outcome, alongside the normalization of hematopoiesis and improvement in bone marrow fibrosis, there will be an increasing need for surrogate measures of survival for use in the early stages of trials. As such, the design of future clinical trials will require re-evaluation and updating to incorporate informative parameters and end points with standardized definitions and methodologies., (© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)
- Published
- 2022
- Full Text
- View/download PDF
26. Temporal efficacy of antimicrobials against aerobic bacteria isolated from equine endometritis: an Italian retrospective analysis (2010-2017).
- Author
-
Pisello L, Rampacci E, Stefanetti V, Beccati F, Hyatt DR, Coletti M, and Passamonti F
- Subjects
- Animals, Bacteria, Aerobic isolation & purification, Endometritis drug therapy, Endometritis microbiology, Female, Horse Diseases microbiology, Horses, Italy, Retrospective Studies, Treatment Outcome, Anti-Infective Agents pharmacology, Bacteria, Aerobic drug effects, Endometritis veterinary, Horse Diseases drug therapy
- Abstract
This study aimed to describe bacteria isolated from the reproductive tract of mares and to identify changes in antimicrobial susceptibility patterns to those antibiotics commonly used for the treatment of equine endometritis. A total of 4122 equine uterine swabs were collected from mares suffering from reproductive tract disorders in the period 2010-2017. Aerobic culture and antimicrobial susceptibility testing using agar disc diffusion were performed on each sample. Aerobic bacteria were isolated from 3171 of 4122 (76.9 per cent) samples. The most frequently isolated microorganisms were Escherichia coli (885/3171, 27.9 per cent) and Streptococcus equi subspecies zooepidemicus (791/3171, 24.9 per cent), confirming previous findings from the literature. Antimicrobial susceptibility patterns of E coli , S equi subspecies zooepidemicus and Klebsiella pneumoniae changed over time. A statistically significant decrease in antimicrobial efficacy of cefquinome against E coli was observed over the years, as well as of ampicillin, cefquinome and penicillin against S equi subspecies zooepidemicus The high frequency of resistant bacteria isolated in the present work proceeds in the same way as indicated by surveillance data on the huge antibiotic use in Italy. As a result, testing and monitoring programmes of antimicrobial efficacy are crucial to consciously using antibiotics and preserving their effectiveness both for veterinary and human medicine., Competing Interests: Competing interests: None declared., (© British Veterinary Association 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
27. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
- Author
-
Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, and Mesa RA
- Subjects
- Case-Control Studies, Female, Humans, Male, Middle Aged, Polycythemia Vera physiopathology, Polycythemia Vera psychology, Primary Myelofibrosis physiopathology, Primary Myelofibrosis psychology, Quality of Life, Sexual Behavior, Sexuality, Surveys and Questionnaires, Thrombocythemia, Essential physiopathology, Thrombocythemia, Essential psychology, Myeloproliferative Disorders physiopathology, Myeloproliferative Disorders psychology, Sexual Dysfunction, Physiological etiology, Sexual Dysfunctions, Psychological etiology
- Abstract
Background: Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality-related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms., Methods: A total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age-matched, healthy control population., Results: Overall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN-SAF score of 3.6 vs 2.0; P<.001), with 64% of patients with MPN describing some degree of sexual dysfunction and 43% experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular-related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids., Conclusions: The results of the current study identify the topic of sexuality as a prominent issue for the MPN population, and this area would appear to benefit from additional investigation and management. Cancer 2016;122:1888-96. © 2016 American Cancer Society., (© 2016 American Cancer Society.)
- Published
- 2016
- Full Text
- View/download PDF
28. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
- Author
-
Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, and Vannucchi AM
- Subjects
- Adult, Aged, Aged, 80 and over, Anemia blood, Anemia chemically induced, Anemia pathology, Contraindications, Drug-Related Side Effects and Adverse Reactions classification, Drug-Related Side Effects and Adverse Reactions pathology, Female, Granulocytes pathology, Hematocrit, Humans, Hydroxyurea adverse effects, Janus Kinase 1 antagonists & inhibitors, Janus Kinase 2 antagonists & inhibitors, Male, Middle Aged, Nitriles, Polycythemia Vera blood, Polycythemia Vera pathology, Pyrimidines, Thrombocytopenia blood, Thrombocytopenia chemically induced, Thrombocytopenia pathology, Young Adult, Janus Kinase 1 genetics, Janus Kinase 2 genetics, Polycythemia Vera drug therapy, Pyrazoles administration & dosage
- Abstract
Background: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with somatic gain-of-function mutations of Janus kinase-2 (JAK2). Therapeutic options are limited in patients with advanced disease. Ruxolitinib, an oral JAK1/JAK2 inhibitor, is active in preclinical models of PV. The long-term efficacy and safety of ruxolitinib in patients with advanced PV who are refractory or intolerant to hydroxyurea were studied in a phase 2 trial., Methods: Response was assessed using modified European LeukemiaNet criteria, which included a reduction in hematocrit to <45% without phlebotomy, resolution of palpable splenomegaly, normalization of white blood cell and platelet counts, and reduction in PV-associated symptoms., Results: Thirty-four patients received ruxolitinib for a median of 152 weeks (range, 31 weeks-177 weeks) or 35.0 months (range, 7.1 months-40.7 months). Hematocrit <45% without phlebotomy was achieved in 97% of patients by week 24.Only 1 patient required a phlebotomy after week 4. Among patients with palpable splenomegaly at baseline, 44% and 63%, respectively, achieved nonpalpable spleen measurements at weeks 24 and 144. Clinically meaningful improvements in pruritus, night sweats, and bone pain were observed within 4 weeks of the initiation of therapy and maintained with continued treatment. Ruxolitinib treatment also reduced elevated levels of inflammatory cytokines and granulocyte activation. Thrombocytopenia and anemia were the most common adverse events.Thrombocytopenia of grade 3 or anemia of grade 3 (according to National Cancer Institute Common Terminology Criteria for Adverse Events,version 3.0) occurred in 3 patients each (9%) (1 patient had both) and were managed with dose modification., Conclusions: Ruxolitinib was generally well tolerated and provided rapid and durable clinical benefits in patients with advanced PV who were refractory or intolerant to hydroxyurea.
- Published
- 2014
- Full Text
- View/download PDF
29. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
- Author
-
Squizzato A, Romualdi E, Passamonti F, and Middeldorp S
- Subjects
- Anticoagulants administration & dosage, Anticoagulants adverse effects, Aspirin adverse effects, Humans, Platelet Aggregation Inhibitors adverse effects, Polycythemia Vera mortality, Randomized Controlled Trials as Topic, Thrombocythemia, Essential mortality, Aspirin administration & dosage, Platelet Aggregation Inhibitors administration & dosage, Polycythemia Vera drug therapy, Thrombocythemia, Essential drug therapy, Thrombosis prevention & control
- Abstract
Background: Polycythaemia vera and essential thrombocythaemia are chronic Philadelphia-negative myeloproliferative neoplasms that increase the risk of arterial and venous thrombosis, as well as bleeding. In addition to the different therapeutic strategies available, an antiplatelet drug is often used to reduce thrombotic risk., Objectives: To quantify the benefit and harm of antiplatelet drugs for long-term primary and secondary prophylaxis of arterial and venous thrombotic events in patients with polycythaemia vera or essential thrombocythaemia., Search Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Library (Issue 1 2012), MEDLINE (1966 to 2012), and EMBASE (1980 to 2012), as well as online registers of ongoing trials and conference proceedings. The date of the last search was October 2012., Selection Criteria: We included all randomised controlled trials (RCTs) comparing long-term (>6 months) use of an antiplatelet drug versus placebo or no treatment in participants with polycythaemia vera or essential thrombocythaemia, as diagnosed by established international criteria, with data for at least one of the selected outcomes., Data Collection and Analysis: Using a pre-defined extraction form, two review authors independently screened results, extracted data, and assessed quality. We planned to analyse the following outcomes: mortality from arterial and venous thrombotic events (primary efficacy outcome), mortality from bleeding episodes (primary safety outcome), fatal and non-fatal arterial thrombotic events, fatal and non-fatal venous thrombotic events, micro-circulation events, transient neurological and ocular manifestations, major and minor bleeding episodes, and all-cause mortality and any adverse events. We based quantitative analysis of outcome data on an intention-to-treat principle. We used the pooled odds ratio (OR) with 95% confidence interval (CI) with a fixed-effect model (Mantel-Haenszel) to estimate the overall treatment effect., Main Results: We identified no new studies from the updated searches. We included in this review two RCTs for a total of 630 participants. Both RCTs included participants with an established diagnosis of polycythaemia vera and with no clear indication or contraindication to aspirin therapy. We judged both studies to be of moderate quality. Published data from both studies were insufficient for a time-to-event data analysis and for some of the primary and secondary outcomes that we planned. The use of low-dose aspirin, compared with placebo, was associated with a lower risk of fatal thrombotic events (although this benefit was not statistically significant (OR 0.20, 95% CI 0.03 to 1.14; P = 0.07). No data on mortality from bleeding episodes were available. A non-significant benefit of aspirin was shown for all-cause mortality (OR 0.46, 95% CI 0.21 to 1.01; P = 0.05). No increase in the risk of major bleeding was reported in participants taking aspirin compared with those given placebo (OR 0.99, 95% CI 0.23 to 4.36; P = 0.99), and a non-significant increase with aspirin treatment was shown for minor bleeding (OR 1.85, 95% CI 0.90 to 3.79; P = 0.09). No published studies have reported findings in participants with essential thrombocythaemia or in the study of other antiplatelet drugs., Authors' Conclusions: For patients with polycythaemia vera who have no clear indication or contraindication to aspirin therapy, available evidence suggests that the use of low-dose aspirin, when compared with no treatment, is associated with a statistically non-significant reduction in the risk of fatal thrombotic events and all-cause mortality, without an increased risk of major bleeding.
- Published
- 2013
- Full Text
- View/download PDF
30. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
- Author
-
Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, and Cazzola M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Disease Progression, Female, Genetic Testing, Granulocytes metabolism, Humans, Male, Middle Aged, X Chromosome Inactivation genetics, Chromosomes, Human, X genetics, Janus Kinase 2 genetics, Mutation, Missense, Myeloproliferative Disorders genetics, Pedigree
- Abstract
Background: A somatic gain-of-function mutation of the Janus kinase 2 (JAK2) gene has been identified in chronic myeloproliferative disorders, which appear to have a sporadic occurrence in most individuals. The authors studied the biologic significance of the JAK2 (V617F) mutation in familial myeloproliferative disorders., Methods: Twenty pedigrees with familial chronic myeloproliferative disorders were identified through an investigation of family history in 264 patients with sporadic myeloproliferative disorders. A quantitative real-time polymerase chain reaction (qRT-PCR)-based allelic discrimination assay was employed for the detection of the V617F mutation in circulating granulocytes and T lymphocytes. An analysis of X-chromosome inactivation pattern was performed in female patients., Results: Fourteen families had homogeneous phenotypes, and 6 families had mixed phenotypes. By using a qRT-PCR-based allelic discrimination assay, the JAK2 (V617F) mutation was detected in circulating granulocytes from 20 of 31 patients, but the mutation was not detected in T lymphocytes. Granulocyte mutant alleles ranged from 2.1% to 91.5% and, on average, increased with time. Discordant distribution of the JAK2 (V617F) mutation was observed in siblings with polycythemia vera. The proportion of granulocytes that carried the JAK2 (V617F) mutation was lower than the proportion of clonal granulocytes, as determined in an analysis of X-chromosome inactivation patterns in female patients., Conclusions: The current findings indicated that the JAK2 (V617F) mutation represents an acquired somatic mutation in patients with familial chronic myeloproliferative disorders and probably occurs as a secondary genetic event in the background of preexisting clonal hematopoiesis. Thus, a genetic predisposition to acquisition of JAK2 (V617F) is inherited in families with myeloproliferative disorders., ((c) 2006 American Cancer Society.)
- Published
- 2006
- Full Text
- View/download PDF
31. Leukemic transformation of polycythemia vera: a single center study of 23 patients.
- Author
-
Passamonti F, Rumi E, Arcaini L, Castagnola C, Lunghi M, Bernasconi P, Giovanni Della Porta M, Columbo N, Pascutto C, Cazzola M, and Lazzarino M
- Subjects
- Acute Disease, Aged, Chromosome Aberrations, Humans, Karyotyping, Leukemia drug therapy, Middle Aged, Polycythemia Vera genetics, Leukemia etiology, Polycythemia Vera complications
- Abstract
Background: Acute leukemia (AL) may occur as rare and late event of polycythemia vera (PV)., Methods: The current study included 23 patients who developed acute leukemia in a cohort of 414 consecutive PV patients with long-term observation (3208 person years of follow-up). Kaplan-Meier Product-Limit method was used to estimate the cumulative probability of survival; Gehan-Wilcoxon test was applied to compare survival in different groups of patients., Results: Median age was 68 years, and 18 patients (78%) were > 60 years of age. At diagnosis of AL, most patients had a white blood count > 10 x 10(9)/L (n = 17; 74%), Hgb < 10 g/dL (n = 13; 57%), and platelet count > 50 x 10(9)/L (n = 17; 74%). Of 14 patients in whom cytogenetic analysis was available at leukemic transformation, 12 showed high-risk abnormalities including complex karyotype (n = 10), del (7)(q22) sole (n = 1) and del (X)(q26) sole (n = 1), whereas 2 had a normal karyotype. In patients whose karyotype was available at diagnosis of PV, cytogenetic evolution was documented at progression to AL. Treatment consisted of supportive care and/or low-dose chemotherapy (n = 15), or induction chemotherapy (n = 8). This included idarubicin plus cytarabine (n = 3), high-dose cytarabine (n = 4), and fludarabine-based regimen (n = 1). Allogenic stem cell transplantation was offered to a single patient, who is alive at Day + 70. The outcome of patients was poor, with a median survival of 2.9 months (range, 0.6-20.1 mos), with no significant differences between palliation and intensive treatments., Conclusions: AL following PV has distinct clinical and biologic features. Outcome of patients is poor irrespective of the treatment employed.
- Published
- 2005
- Full Text
- View/download PDF
32. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
- Author
-
Arcaini L, Paulli M, Boveri E, Vallisa D, Bernuzzi P, Orlandi E, Incardona P, Brusamolino E, Passamonti F, Burcheri S, Schena C, Pascutto C, Cavanna L, Magrini U, and Lazzarino M
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Disease-Free Survival, Female, Humans, Interferons therapeutic use, Lymphoma, B-Cell, Marginal Zone drug therapy, Lymphoma, Non-Hodgkin drug therapy, Male, Middle Aged, Prognosis, Retrospective Studies, Seroepidemiologic Studies, Splenic Neoplasms drug therapy, Splenomegaly etiology, Hepacivirus pathogenicity, Lymph Nodes pathology, Lymphoma, B-Cell, Marginal Zone pathology, Lymphoma, B-Cell, Marginal Zone virology, Lymphoma, Non-Hodgkin pathology, Lymphoma, Non-Hodgkin virology, Neoplasm Staging, Splenic Neoplasms pathology, Splenic Neoplasms virology
- Abstract
Background: Splenic and nodal marginal zone lymphomas (MZL) are subtypes of marginal zone-derived neoplasms. Due to their rarity, little is known concerning their relation, pattern of dissemination, and treatment outcome., Methods: The authors analyzed the clinicopathologic features and outcome of 43 patients (34 patients with splenic MZL and 9 patients with nodal MZL). All lesional tissues obtained at diagnosis were reviewed histologically., Results: Among the patients with splenic MZL, 30 patients had Stage IV disease (based on the Ann Arbor staging system). Twenty-six patients presented with splenomegaly with or without limited involvement of abdominal lymph nodes, whereas 7 patients showed disease extension to superficial lymph nodes. Hepatitis C virus (HCV) serology was positive in 35% of patients. Seventeen patients underwent splenectomy, 8 patients received chemotherapy, and 7 patients were followed without initial treatment. Interferon produced a lymphoma response in three of four HCV positive patients. Of 27 treated patients, 13 patients achieved a complete response, and 12 patients achieved a partial response. The median event-free survival (EFS) was 3.3 years (5.1 years for patients with disease confined to the abdomen and 2.1 years for patients with disease extension to superficial lymph nodes). Among nine patients with nodal MZL, four patients had Stage IV disease. HCV serology was positive in two patients. Five patients responded to chemotherapy. The median EFS was 2.8 years. The median overall survival was not reached for patients with both types of MZL., Conclusions: The results of the current study demonstrated that splenic and nodal MZL are indolent lymphomas with different presenting features but common morphologic and biologic characteristics, including high HCV seroprevalence. Studies will be required to identify specific biologic markers and to define the best treatment., (Copyright 2003 American Cancer Society.)
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.